Roche had rights beginning in 2003 till December 2018 for the Anti-PS Program according to the SEC filing info above
Looks like Roche is no longer bearer of those rights and Oncologie is steering the deals ....
Imagine if Roche was a bit upset and Ronin Capital Management just so happened to have someone Cramerlike in John Springs Stafford trying to say PS Targeting was not as worthy as others KNOW
Imaging and AI based upon Anti-PS programs / Targeting etc ....is priceless